These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30166233)

  • 21. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan.
    Mukai R; Kataoka K; Tanaka K; Miyara Y; Maruko I; Nakayama M; Watanabe Y; Yamamoto A; Wakatsuki Y; Onoe H; Wakugawa S; Terao N; Hasegawa T; Kawai M; Maruko R; Itagaki K; Honjo J; Okada AA; Mori R; Koizumi H; Iida T; Sekiryu T
    Sci Rep; 2024 May; 14(1):11681. PubMed ID: 38778065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration.
    Siktberg J; Kim SJ; Sternberg P; Patel S
    Eye (Lond); 2023 Jun; 37(9):1844-1849. PubMed ID: 36127425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen.
    Cozzi M; Monteduro D; Esposito RA; Spooner KL; Fraser-Bell S; Staurenghi G; Romano F; Airaldi M; Chang AA; Invernizzi A
    Eye (Lond); 2024 Jan; 38(1):161-167. PubMed ID: 37393395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-Year Results of a Treat and Extend Regimen with Aflibercept in Caucasian Patients with Pachychoroid Neovasculopathy.
    Montero Hernández J; Remolí Sargues L; Monferrer Adsuara C; Castro Navarro V; Navarro Palop C; Cervera Taulet E
    Semin Ophthalmol; 2023 May; 38(4):352-357. PubMed ID: 36987548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration.
    Izquierdo-Serra J; Martin-Pinardel R; Moll-Udina A; Bernal-Morales C; Garay-Aramburu G; Sanchez-Monroy J; Arruabarrena C; Fernandez-Hortelano A; Figueroa MS; Abraldes M; Lavid de Los Mozos FJ; Zapata MA; Ruiz-Moreno JM; Broc-Iturralde L; Gonzalez-Guijarro J; Escobar-Barranco JJ; Gallego-Pinazo R; Parrado-Carrillo A; Dotti-Boada M; Alforja S; Figueras-Roca M; Barthelmes D; Gillies MC; Casaroli-Marano RP; Zarranz-Ventura J;
    Ophthalmol Retina; 2024 Apr; 8(4):350-359. PubMed ID: 37924946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacillary Detachment in Neovascular Age-Related Macular Degeneration: Incidence, Clinical Features, and Response to Anti-VEGF Therapy.
    Yordi S; Sarici K; Cetin H; Lunasco LM; Le TK; Sevgi DD; Zahid R; Meng X; Reese JL; Srivastava SK; Ehlers JP
    Ophthalmol Retina; 2022 Nov; 6(11):1061-1069. PubMed ID: 35654365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naïve age-related macular degeneration.
    Ota H; Kataoka K; Asai K; Takeuchi J; Nakano Y; Nakamura K; Todoroki T; Nishiguchi KM
    Graefes Arch Clin Exp Ophthalmol; 2024 May; ():. PubMed ID: 38758378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of stoppage and recurrence of choroidal neovascularization with a Treat- Extend-Stop protocol: 4-year follow-up.
    Garay-Aramburu G; Rodriguez-Feijoo D; Aldazabal-Echeveste M; Del Barrio Z; Eiras-Fernández A; Piñero DP; Larrauri-Arana A
    J Fr Ophtalmol; 2023 Dec; 46(10):1204-1211. PubMed ID: 37658033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-year outcomes of intravitreal aflibercept injection for neovascular age-related macular degeneration with 'observe before treat-and-extend' method.
    Moon JY; Kim HJ; Cho SC
    Korean J Ophthalmol; 2024 Aug; ():. PubMed ID: 39160663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
    Lanzetta P; Korobelnik JF; Heier JS; Leal S; Holz FG; Clark WL; Eichenbaum D; Iida T; Xiaodong S; Berliner AJ; Schulze A; Schmelter T; Schmidt-Ott U; Zhang X; Vitti R; Chu KW; Reed K; Rao R; Bhore R; Cheng Y; Sun W; Hirshberg B; Yancopoulos GD; Wong TY;
    Lancet; 2024 Mar; 403(10432):1141-1152. PubMed ID: 38461841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.
    Huang CH; Lai TT; Yang CH; Hsieh YT
    Ophthalmol Ther; 2024 Jan; 13(1):385-396. PubMed ID: 37995014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Choroidal remodeling following different anti-VEGF therapies in neovascular AMD.
    Boscia G; Pozharitskiy N; Grassi MO; Borrelli E; D'Addario M; Alessio G; Boscia F; Viggiano P
    Sci Rep; 2024 Jan; 14(1):1941. PubMed ID: 38253789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of neovascular age-related macular degeneration: Taiwan expert consensus.
    Yeung L; Hsieh YT; Yang CH; Chen LJ; Chen SJ; Cheng CK; Sheu SJ; Tsai CY; Wu TT; Wu WC; Chen SN
    J Formos Med Assoc; 2021 Dec; 120(12):2061-2071. PubMed ID: 34274193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD.
    Kamao H; Mitsui E; Date Y; Goto K; Mizukawa K; Miki A
    J Ophthalmol; 2024; 2024():3673930. PubMed ID: 38322501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-year outcome of brolucizumab for neovascular age-related macular degeneration in Japanese patients.
    Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Tsukii R; Takahashi H; Kawashima H; Yanagi Y
    Sci Rep; 2024 Jan; 14(1):2451. PubMed ID: 38291120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration.
    Korobelnik JF; Chaudhary V; Mitchell P; Kang SW; Tadayoni R; Allmeier H; Lee J; Zhang X; Machewitz T; Bailey C
    Ophthalmol Ther; 2024 Mar; 13(3):725-738. PubMed ID: 38198053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration.
    Chandra S; Raimondi R; Lim A; Mohan A; Melmane S; Menon G; Chandran M; Sivaprasad S; Burton BJL; Kotagiri A
    Eye (Lond); 2024 Jul; ():. PubMed ID: 38971923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic.
    Stepanov A; Studnicka J; Veith M; Nemec P; Vyslouzilova D; Koubek M; Nemcansky J
    Eur J Ophthalmol; 2022 Oct; ():11206721221132619. PubMed ID: 36254407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term follow up of patients with MNV3 treated with intra-vitreal Aflibercept.
    Browning AC; Grinton ME; Quinn S; Jain T; Manikavasagar V; Aftab AM
    Eur J Ophthalmol; 2024 Sep; 34(5):1562-1568. PubMed ID: 38304945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-Term Real-World Outcomes of Intensive Aflibercept Injection for Refractory Neovascular Age-Related Macular Degeneration.
    Son W; Sagong M
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.